Introduction
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that belongs to the phosphatidylinositol 3-kinase (PI3K)-related kinase family and is a key regulator of cell growth, proliferation, metabolism, and survival [1] . mTOR plays an evolutionarily conserved role in integrating the signals from growth factors [2] . Among various pathways upstream of mTOR, PI3K/Akt signaling is considered the most important [2] .
Growth factors including epidermal growth factor (EGF) and insulin activate the mTOR pathway via PI3K/Akt signaling and stimulate cell cycle progression and proliferation [3, 4, 5] . Regulation of the mTOR pathway plays an important physiological and pathological role in the central nervous system (CNS).
Glutamate, a principal excitatory amino acid mediating fast neurotransmission in the CNS, plays a central role in normal brain functions including cognition, memory and learning. However, excessive elevation of the extracellular glutamate concentration mediates excitotoxicity and causes neuronal cell death [6] . There is no enzymatic system available for metabolizing glutamate in the extracellular space; the only way to maintain glutamate homeostasis is through glutamate uptake via glutamate transporters [7] .
Five glutamate transporter subtypes expressed in neurons or glia, including glutamate aspartate transporter (GLAST, also known as EAAT1), glutamate transporter 1 (GLT1, also known as EAAT2), EAAC1, EAAT4, and EAAT5, have been identified and characterized. GLT1, predominantly located on astrocytes, is responsible for up to 90% of glutamate clearance in adult brain tissue [7] .
Reductions in or dysfunctions of GLT1 have been documented in several neurological disorders including stroke [8] , Alzheimer's disease [9] , and amyotrophic lateral sclerosis [10] . These findings emphasize the importance of GLT1 in astrocytes for normal brain function.
In the present study, we prepared astrocytes incubated in astrocyte-defined medium (ADM), which contained a number of supplementary agents including the growth factors EGF, bFGF, and insulin [11, 12] . It has been demonstrated that GLT1 expression is increased by EGF, and EGF-Akt signals regulate GLT1 expression [13] . Because it is a well-known substrate of Akt, mTOR has been proposed to have a role in GLT1 regulation.
We therefore investigated whether mTOR is involved in GLT1 regulation using ADM-cultured astrocytes.
Materials and methods
Astrocyte cultures. The use of experimental animals in this study was conducted in accordance with the ethical guidelines of the Kyoto University Animal Experimentation Committee. Primary astrocyte cultures were obtained from postnatal day 1 (P1) Wistar rat cortex (Nihon SLC, Shizuoka, Japan). Briefly, dissociated cells were seeded into 75-cm 2 tissue culture flasks and incubated for 20-24 days in Eagle's minimum essential medium (EMEM) supplemented with 10% FBS and 50 µg/ml kanamycin at 37ºC in a 5% CO 2 /95% air humidified incubator. Flasks were shaken at 400 rpm (10 min, 37ºC) and then at 220 rpm (15 hr, 37ºC DMEM was supplemented with transferrin (50 µg/ml), sodium selenite (5.2 ng/ml), fibronectin (1.5 µg/ml), heparin sulfate (0.5 µg/ml), EGF (10 ng/ml), bFGF (5 ng/ml), insulin (5 µg/ml), and kanamycin (50 µg/ml) [12] . Cells in the culture were shown to be astrocytes with a purity of 97 ± 2% after characterization by immunostaining using a primary anti-GFAP antibody.
L-[

Results
ADM induces GLT1 expression and Akt and mTOR phosphorylation
GLT1 protein was detectable in astrocytes incubated in DMEM with 10% FBS (control; CTL). When astrocytes were incubated in astrocyte-defined medium (ADM) as previously reported [11, 12] , GLT1 expression was upregulated. Western blot analysis
showed that GLT1 expression increased in a time-dependent manner in ADM and was significantly higher than expression in the CTL after a one-day incubation. In contrast,
GLAST, another glutamate transporter mainly located on astrocytes, was not affected
To determine whether the change in GLT1 expression affected glutamate uptake To determine whether the Akt/mTOR pathway was activated in ADM-cultured astrocytes, we examined the phosphorylation level of Akt at Ser473 and the phosphorylation level of mTOR at Ser2448. The results showed that Akt was phosphorylated immediately after the medium was replaced with ADM, and the phosphorylation reached its peak 6 hr after the medium replacement. This peak was followed by a gradual decrease, although the increased phosphorylation was sustained even after four days (Fig. 1A, 1D ).
Subsequent phosphorylation of mTOR was found after the beginning of Akt phosphorylation, and mTOR phosphorylation reached its peak 12 hr after the medium replacement. As for Akt phosphorylation, this peak was followed by a gradual decrease, although the increased phosphorylation was sustained even after four days (Fig. 1A,   1E ).
GLT1 upregulation was found after a one-day incubation, suggesting that Akt/mTOR signaling might lead to GLT1 protein synthesis (Fig. 1A) .
mTOR is a downstream target of PI3K/Akt in the pathway regulating GLT1 expression
To determine whether the Akt/mTOR pathway is involved in GLT1 expression, the effects of PI3K inhibition on GLT1 expression were examined. Treatment with a selective PI3K inhibitor LY294002 (from 0.3 µM to 10 µM) for 4 days decreased Akt phosphorylation (Ser473) in a concentration-dependent manner in four-day ADM-cultured astrocytes ( Fig. 2A, 2B ). In addition, mTOR phosphorylation (Ser2448), and GLT1 protein levels were also suppressed by LY294002, indicating that mTOR is a downstream target of PI3K ( Fig. 2A, 2C, 2D ).
For the Akt inhibition, we selected Akt inhibitor VIII since it selectively blocks basal and stimulated phosphorylation of Akt1/Akt2. Treatment with Akt inhibitor VIII (from 0.03 µM to 1 µM) for 4 days also decreased Akt phosphorylation (Ser473), mTOR phosphorylation (Ser2448), and GLT1 protein levels in a concentration-dependent manner in four-day ADM-cultured astrocytes ( Fig. 2A , E-G).
It is well known that PI3K phosphorylates Akt. Based on these data, it is hypothesized that mTOR is a downstream target of Akt.
Phosphorylation of mTOR is involved in GLT1 expression
Rapamycin, an antifungal and immunosuppressant agent, complexes with FKBP-12 and binds mTOR and has been reported to inhibit the activity of mTOR and mTOR phosphorylation at Ser2448. Treatment with rapamycin (from 1 nM to 30 nM) for 4 days decreased mTOR phosphorylation (Ser2448) and GLT1 protein levels in four-day ADM-cultured astrocytes (Fig. 3A-3D ). However, rapamycin had no effect on Akt phosphorylation (Ser473) (Fig. 3A-3D ). Based on these data, it is hypothesized that PI3K-Akt is upstream of mTOR.
To demonstrate that the ADM-induced increase in GLT1 levels is caused by the protein synthesis and not by the attenuation of degradation and that mTOR plays a key role in this cascade, we evaluated GLT1 mRNA levels by real-time PCR. Incubation in ADM caused an increase in GLT1 mRNA levels, and rapamycin significantly reduced the ADM-induced increase in GLT1 mRNA (Fig. 3G) . These results suggest that mTOR activation is involved in the increase of GLT1 mRNA.
We next investigated whether the mTOR inhibition-induced decrease in GLT1 expression affected the glutamate uptake capacity of four-day ADM-cultured astrocytes by performing a L-[ 3 H]glutamate uptake assay. Treatment with rapamycin decreased the ADM-induced increase in glutamate uptake in a time-and concentration-dependent manner (Fig. 3E, 3F ). These results suggest that glutamate uptake activity is correlated with GLT1 protein levels.
Based on these results, it is hypothesized that mTOR is downstream of the PI3K/Akt pathway that regulates GLT1 protein levels and activity.
Discussion
In this study, we revealed that mTOR is a downstream target of Akt in the pathway regulating GLT1 expression. This conclusion is based on the following results obtained from experiments with ADM-cultured astrocytes: (1) ADM induced Akt/mTOR pathway activation and GLT1 expression; (2) Akt inhibition reduced mTOR phosphorylation and GLT1 expression; and (3) mTOR inhibition reduced GLT1 expression and glutamate uptake capacity but did not affect Akt phosphorylation.
mTOR is responsive to a diverse group of cellular signals including growth factors, and mTOR is a key regulator of protein translation. Growth factors or related hormones activate receptor tyrosine kinases and G protein coupled receptors, and several signal transduction pathways are subsequently activated [17] . PI3K/Akt pathway and the Ras/Erk (extracellular signal regulated kinase) pathway stimulate mTOR [18] . Growth factors and insulin in ADM would activate these signal cascade.
Activated mTOR subsequently signals to various components of the translation initiation machinery through direct or indirect phosphorylation. mTOR-mediated phosphorylation activates ribosomal S6 kinase, results in its dissociation from eukaryotic initiation factor complex 3 (eIF3) [19] . Subsequently 4E-binding protein 1 (4E-BP-1) dissociates from the cap complex to promote protein translation [19] . GLT1 upregulation might be mediated via these signals, although the downstream transcription factor(s) binding the GLT1 promoter need to be identified in future experiments.
Cells have several independent mechanisms, among them mTOR-mediated regulation of translation initiation. Interestingly, GLAST expression was not altered by mTOR inhibition. GLT1 and GLAST are regulated by different signals.
It has been reported that mTOR signaling is important for astrocyte survival during ischemia. During oxygen-glucose depletion, mTOR signaling is impaired in astrocytes, resulting in a defect in Bad phosphorylation and in the expression of anti-apoptotic factors Bcl-2 and Bcl-xl, leading to dysfunction or death of astrocytes [20] . Normal GLT1 expression and glutamate uptake capacity are also impaired during ischemia [21] .
Oxygen-glucose depletion or ischemia might impair mTOR signaling, and as a consequence, GLT1 expression might be downregulated.
Conversely, activation of mTOR signaling would upregulate GLT1, which could reduce excessive extracellular glutamate to decrease the size of ischemic regions or the impact of neurodegenerative diseases.
Our novel findings that mTOR is involved in the PI3K/Akt-induced upregulation of GLT1 contribute to the understanding of the pathogenesis of ischemia and neurodegenerative diseases and may be important in developing therapeutic strategies against these conditions.
In conclusion, this is the first report showing that mTOR is downstream of PI3K/Akt in the pathway regulating GLT1 expression, and our finding reveals a new mechanism underlying GLT1 regulation in astrocytes. 
